KM Research Hub

FIXED FIVE-YEAR COHORT AUDIT

近五年文献重新检索与对照

旧查询复现与严格 v3 为主比较;历史库存和广召回仅用于解释差异与检查漏检。

complete · complete 汇总 CSV 明细 CSV
固定日期2021-07-29 至 2026-07-29
入排版本oncology-definitive-rct-km-v3
并集论文20925
批次键five-year-20210729-20260729-v1

四个独立队列

数字为批次中保存的原始 PMID 数,不会随着日常监测改变。

历史库存参照组 13065 audit_reference · server-inventory-snapshot-v1
旧查询复现组 7069 primary_legacy · legacy-phase3-fulltext-v1
严格 v3 主组 4707 primary_new · oncology-phase3-survival-strict-v3
v3 广召回影子组 13640 recall_audit · oncology-phase3-survival-discovery-v3

集合关系

交集和差集均按 PMID 精确计算;DOI 只用于明细核对。

比较交集左组独有右组独有
历史库存 ↔ 旧查询复现 7028 6037 41
旧查询复现 ↔ 严格 v3 2464 4605 2243
严格 v3 ↔ 广召回影子组 4707 0 8933
严格查询未命中、但影子组经 v3 筛选后合格 166 篇

元数据入排

20925 / 20925 已完成

KM 证据

仅检查 v3 元数据合格论文,不运行曲线数字化。

论文明细

共 8933 篇;可组合筛选集合关系、入排结果和 KM 证据。

论文队列集合关系v3 入排KM 证据
Model-Informed Drug Development of Subcutaneous Nivolumab: Comparison of Pharmacokinetic Analysis Methodologies Using Clinical Trial Simulation. PMID 40990036 · CPT Pharmacometrics Syst Pharmacol · 2025-Dec The record is an oncology, human, randomized, phase III trial with a drug intervention, but it does not present original results for a time-to-event efficacy endpoint. The endpoints are pharmacokinetic exposure metrics, and the analysis is methodological (comparing modeling approaches), not the formal primary efficacy analysis of the trial.
H L B
旧查询独有 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Artificial intelligence and radiomics biomarkers for treatment response prediction in advanced HER2-negative breast cancer. PMID 40974664 · Breast · 2025-Dec 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
DISCERN: A Randomized Pilot Study Comparing Dual Versus Single Immune Checkpoint Blockade Plus Chemotherapy in PD-L1 Negative Advanced Non-Small Cell Lung Cancer. PMID 40947345 · Clin Lung Cancer · 2025-Dec This is a protocol for a randomized pilot study (Phase not specified, but described as a pilot) with a primary endpoint of ctDNA molecular response. It does not present results for a definitive Phase III/IIIb or Phase II/III randomized trial with a primary/key secondary time-to-event efficacy endpoint.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
First-Line Tislelizumab Plus Chemotherapy in Advanced Non-Squamous Non-Small Cell Lung Cancer: PD-L1 ≥ 50% Subgroup Analysis from the RATIONALE-304 Trial. PMID 40946254 · Oncol Ther · 2025-Dec 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Boron neutron capture therapy (BNCT) phase I clinical trial for newly diagnosed glioblastoma by newly developed accelerator at University of Tsukuba. PMID 40945116 · Appl Radiat Isot · 2025-Dec 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Phase 2 trial of personal dendritic cell vaccines in newly diagnosed glioblastoma: 3-year follow-up and correlations with survival. PMID 40938661 · Hum Vaccin Immunother · 2025-Dec 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Cytokine biomarkers and their relationship to symptoms and quality of life in people with HIV-associated Kaposi sarcoma. PMID 40926591 · HIV Med · 2025-Dec The record is a secondary analysis of a randomized trial examining cytokine biomarkers and quality of life in HIV-associated Kaposi sarcoma. It does not report a primary or key secondary time-to-event efficacy endpoint (e.g., OS, PFS, DFS), and a drug-containing intervention is not explicitly described in the abstract. The study phase is not specified as Phase III/IIIb or Phase II/III. Therefore, it does not meet the eligibility criteria for the oncology Kaplan-Meier digitization cohort.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Quality Matters: Effect of High-Quality Early Palliative Care in Advanced Cancer. PMID 40907620 · J Pain Symptom Manage · 2025-Dec 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Tetra-modality bladder preservation with avelumab for muscle-invasive urothelial cancer: a phase II trial (TRIUMPH-B01). PMID 40851456 · Future Oncol · 2025-Dec 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Cost-Utility Analysis Alongside the GORTEC 2014-01 TPExtreme Trial: TPEx Versus EXTREME as First-Line Treatment in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma. PMID 40848743 · Value Health · 2025-Dec The record describes a cost-utility analysis alongside a randomized trial. While the underlying trial (GORTEC 2014-01 TPExtreme) is a randomized, drug-intervention oncology trial with a time-to-event efficacy endpoint (OS), this specific publication is a health-economic evaluation, not an original formal-result report of the trial's efficacy. It does not present the primary efficacy analysis itself.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Red light photodynamic therapy with 10% aminolevulinic acid gel showed efficacy for treatment of superficial basal cell carcinoma in a randomized, vehicle controlled, double-blind, multicenter phase III study. PMID 40846240 · J Am Acad Dermatol · 2025-Dec While the study is a Phase III, randomized, oncology trial with a drug intervention (10% ALA gel for photodynamic therapy), the primary efficacy endpoint is histological and clinical clearance at a fixed time point (12 weeks), not a time-to-event endpoint like OS, PFS, DFS, EFS, RFS, TTP, Kaplan-Meier, or HR.
H L B
旧查询独有 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Gastric Conditioning Before Ivor Lewis Esophagectomy for Cancer: Long-Term Outcomes From the APIL_2013 Pilot Randomized Controlled Trial. PMID 40820080 · J Surg Res · 2025-Dec 干预为非药物单独策略,未满足药物干预要求。
B
仅广召回影子组 excludednon_drug_intervention pending 0 Figure · 0 Panel · risk -
Guided Mindfulness of Death to Reduce Fear of Death in Cancer Patients: Randomized Controlled Study. PMID 40816694 · J Pain Symptom Manage · 2025-Dec The study is a randomized controlled trial in cancer patients (oncology, human, randomized). However, it is excluded because the intervention is non-drug only (guided mindfulness exercises) and the primary endpoints are symptom/quality-of-life measures (fear of death, suffering), not a time-to-event efficacy endpoint (OS, PFS, DFS, etc.) with Kaplan-Meier or HR analysis.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Safety of liposomal daunorubicin-cytarabine (CPX-351) in secondary AML: Japanese phase 1/2 study and global phase 3 study. PMID 40815417 · Int J Hematol · 2025-Dec 主要研究目的为安全性/毒性或卫生经济学,未见合格 time-to-event 疗效终点。
B
仅广召回影子组 excludedsafety_or_economic_primary_endpoint pending 0 Figure · 0 Panel · risk -
Re: Effect of NeuroSAFE-guided RARP Versus Standard RARP on Erectile Function and Urinary Continence in Patients with Localised Prostate Cancer (NeuroSAFE PROOF): A Multicentre, Patient-blinded, Randomised, Controlled Phase 3 Trial. PMID 40796479 · Eur Urol · 2025-Dec The study is a randomized Phase 3 trial in oncology, but it investigates a surgical intervention (non-drug) and reports functional outcomes, not the required time-to-event efficacy endpoints.
H B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
The evolution of treatment for pediatric advanced stage classic Hodgkin lymphoma - a narrative literature review. PMID 40776670 · Leuk Lymphoma · 2025-Dec 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H B
仅广召回影子组 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Pharmacokinetics of subcutaneous and intravenous bolus doses of morphine in palliative care cancer patients receiving infusion of morphine: A pharmacokinetic substudy of a randomized controlled trial. PMID 40755222 · Br J Clin Pharmacol · 2025-Dec The record is a pharmacokinetic substudy of a randomized trial in palliative care cancer patients. It does not report a primary or key secondary time-to-event efficacy endpoint (OS, PFS, etc.). The phase is not explicitly stated as Phase III/IIIb or Phase II/III. The focus is on pharmacokinetics, not drug intervention efficacy. Therefore, it does not meet eligibility criteria.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Time Dependence of Outcomes in the SPCG-4 Randomized Trial Comparing Radical Prostatectomy and Watchful Waiting in Early Prostate Cancer. PMID 40744802 · Eur Urol · 2025-Dec The record describes a randomized Phase III oncology trial with long-term time-to-event outcomes (prostate cancer mortality). However, it is excluded because it does not involve a drug-containing intervention (surgery vs. observation), which is a required criterion for the cohort.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Re: Effect of NeuroSAFE-guided RARP Versus Standard RARP on Erectile Function and Urinary Continence in Patients with Localised Prostate Cancer (NeuroSAFE PROOF): A Multicentre, Patient-blinded, Randomised, Controlled Phase 3 Trial. PMID 40713359 · Eur Urol · 2025-Dec The record is a title-only entry for a Phase 3 randomized trial in oncology. However, it fails multiple eligibility criteria based on available metadata: (1) No abstract or text to confirm a time-to-event efficacy endpoint (time_to_event: false). (2) The intervention described is surgical (RARP) with no explicit drug component (drug_intervention: false). (3) The 'Re:' prefix in the title and absence of abstract suggest this may not be the original primary result publication (original_result: false). Therefore, it is not eligible.
B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Matching-adjusted indirect comparison of lisocabtagene maraleucel versus axicabtagene ciloleucel for second-line treatment of patients with early relapsed or refractory large B-cell lymphoma. PMID 40708270 · Leuk Lymphoma · 2025-Dec This is a matching-adjusted indirect comparison (MAIC) of two separate CAR-T therapies, not a primary result report of a single randomized trial. While it references Phase III trials, it does not present original trial data for a single intervention. The efficacy analysis focuses on comparing hazard ratios or specific time-to-event outcomes between the two products, but the abstract does not explicitly report or analyze such endpoints (e.g., OS, PFS) for the purpose of this comparison; it states 'no statistically significant differences' without detailing the metric. Therefore, it does not meet the core criterion of being an original formal-result report of a single randomized trial with a primary/key secondary time-to-event efficacy endpoint.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Thirty-Five-Year Follow-Up Real-World Data Revealed the Efficacy of Autologous Formalin-Fixed Tumor Vaccine on Metastatic Breast Cancer-A Target Trial Emulation. PMID 40695705 · Clin Breast Cancer · 2025-Dec This is a retrospective real-world study using target trial emulation, not a randomized controlled trial. It lacks explicit confirmation of being a Phase III/IIIb or Phase II/III randomized trial with a drug-containing intervention as defined by the protocol.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Human papillomavirus (HPV) type 16 and type 18 antibody concentrations after a single dose of bivalent HPV vaccine in girls aged 9-14 years compared with three doses of quadrivalent HPV vaccine in women aged 18-25 years in Costa Rica (PRIMAVERA): a non-randomised, open-label, immunobridging, non-inferiority trial. PMID 40683285 · Lancet Infect Dis · 2025-Dec The record describes a non-randomized, immunobridging trial with immunogenicity endpoints (antibody concentrations and seropositivity), not a randomized trial with a time-to-event efficacy endpoint.
H L B
旧查询独有 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Analytical and Clinical Performance of the VENTANA CLDN18 (43-14A) RxDx Assay in Gastric and Gastroesophageal Junction Adenocarcinoma Tissue Samples in SPOTLIGHT and GLOW. PMID 40680855 · Mod Pathol · 2025-Dec The record describes the performance of a diagnostic assay in the context of Phase III trials but does not appear to be a primary or secondary efficacy result report of the trials themselves. It lacks explicit evidence of randomization and does not present the efficacy data in a way suitable for KM digitization.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Swallowing and Communication Outcomes Post Chemoradiotherapy for Low-Risk Human Papillomavirus (HPV)-Associated Oropharyngeal Squamous Cell Carcinoma: A Substudy of TROG 12.01. PMID 40662470 · Head Neck · 2025-Dec The study is a substudy of a Phase III randomized trial but reports on swallowing and communication outcomes, not on a primary/key secondary time-to-event efficacy endpoint like OS or PFS. Therefore, it does not meet the inclusion criteria for a Kaplan-Meier digitization cohort.
H L B
旧查询独有 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Prophylactic Versus Reactive (PvR) Feeding in Patients Undergoing (Chemo)radiation in Head and Neck Cancers: Results of a Phase III Randomized Controlled Trial. PMID 40662454 · Head Neck · 2025-Dec The trial is an oncology Phase III randomized controlled trial with original results, but it lacks a primary/key secondary time-to-event efficacy endpoint (e.g., OS, PFS, DFS, EFS, RFS, TTP, Kaplan-Meier, or HR). The primary endpoint is incidence of significant weight loss at 6 months, a categorical outcome, not time-to-event. Additionally, the intervention is a non-drug feeding strategy, not a drug-containing intervention.
H L B
旧查询独有 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Sublingual Ketamine as Breakthrough Analgesia in Patients with Advanced Cancer-A Feasibility Randomised Controlled Repeated Cross-over Trial. PMID 40650554 · J Pain Palliat Care Pharmacother · 2025-Dec The study is a randomized controlled feasibility/pilot trial, not a definitive Phase III or Phase II/III trial. The intervention (sublingual ketamine) is for pain management, not as an anti-cancer drug. The primary endpoint is feasibility (attrition rate), not a time-to-event oncology efficacy endpoint.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Study of the effectiveness of different pelvic floor muscle training methods for improving urinary incontinence in patients with prostate cancer after radical prostatectomy. PMID 40642816 · Aging Male · 2025-Dec The study is a randomized controlled trial in human oncology (prostate cancer), but the interventions are non-drug (pelvic floor muscle training and magnetic stimulation), and the primary efficacy outcomes are based on urinary incontinence scores and pad tests, not time-to-event endpoints like OS, PFS, DFS, etc. Therefore, it does not meet the inclusion criteria for a drug-containing intervention with a time-to-event efficacy endpoint.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
The effects of music therapy on pain and anxiety in young nulliparous patients undergoing laparoscopic cystectomy for endometriosis: a randomized controlled trial. PMID 40534482 · J Psychosom Obstet Gynaecol · 2025-Dec 未发现恶性肿瘤人群证据。
B
仅广召回影子组 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Prehabilitation during neoadjuvant chemotherapy results in an enhanced immune response in esophageal adenocarcinoma tumors: A randomized controlled trial. PMID 40499717 · J Sport Health Sci · 2025-Dec The study is a randomized controlled trial in human esophageal adenocarcinoma with a drug-containing intervention (neoadjuvant chemotherapy) and reports clinical outcomes, but it does not report a time-to-event efficacy endpoint (e.g., OS, PFS, DFS) as a primary or key secondary outcome; the primary outcome is tumor immune response (TILs), and clinical outcomes like survival are mentioned only as exploratory without formal analysis.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
RhTSH in aiding dynamic assessment in patients with differentiated thyroid Cancer. PMID 40488858 · Eur J Nucl Med Mol Imaging · 2025-Dec The study is a phase 3 randomized trial in human oncology with a drug intervention and reports original results, but it is not randomized (self-controlled design) and does not include a time-to-event efficacy endpoint (e.g., OS, PFS, DFS).
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Cost-effectiveness of pembrolizumab for the first-line treatment of recurrent or metastatic head and neck squamous cell carcinoma in Colombia. PMID 40417835 · J Med Econ · 2025-Dec 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Effects of exercise on inflammation, circulating tumor cells, and circulating tumor DNA in colorectal cancer. PMID 40107449 · J Sport Health Sci · 2025-Dec The study is a randomized trial in oncology (colorectal cancer) but is ineligible because it lacks a drug intervention (exercise-only) and does not report a primary or key secondary time-to-event efficacy endpoint. The endpoints are biomarker changes. The trial phase is also not definitively established as Phase III/IIIb or Phase II/III.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Impact of stereotactic body radiotherapy after progression in castrate resistant prostate cancer patients undergoing first line abiraterone treatment. A subgroup analysis from ARTO trial (NCT03449719). PMID 39972049 · Prostate Cancer Prostatic Dis · 2025-Dec 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Insights into treatment of patients with mycosis fungoides or Sézary syndrome using mogamulizumab. PMID 39894454 · J Dermatolog Treat · 2025-Dec 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Effects of a combined exercise and dietary intervention on clinical outcomes in patients with ovarian cancer: the Physical Activity and Dietary intervention in OVArian cancer (PADOVA) randomized controlled trial. PMID 39244208 · Int J Gynecol Cancer · 2025-Dec The record describes a Phase II randomized controlled trial (PADOVA trial, NTR6300) evaluating an exercise/dietary intervention alongside standard chemotherapy in ovarian cancer. While it is oncologic, human, randomized, includes a drug intervention, and reports time-to-event data (PFS with HR), it does not meet the core eligibility requirement of being a Phase III/IIIb or Phase II/III trial. The abstract does not state the phase, and the trial registration NTR6300 is for a Phase II study. Furthermore, the primary endpoint of the trial is relative dose intensity (a treatment adherence measure), and PFS is a secondary outcome. Therefore, it is excluded.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Pilot randomized controlled trial of a program to enhance experience and adherence with adjuvant endocrine therapy among women with non-metastatic breast cancer: 12-month quantitative results. PMID 38702555 · J Cancer Surviv · 2025-Dec This is a pilot randomized trial (Phase I/II equivalent) of a psychosocial intervention to improve adherence to adjuvant endocrine therapy in breast cancer. While it involves a drug therapy context, the study is not a definitive Phase III/IIIb trial, and the primary outcome is adherence intention (a psychosocial/behavioral endpoint), not a clinical time-to-event efficacy endpoint like OS or PFS.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Low Social Well-Being in Advanced and Metastatic Prostate Cancer: Effects of a Randomized Controlled Trial of Cognitive Behavioral Stress Management. PMID 38378974 · Int J Behav Med · 2025-Dec 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Short-course hypofractionated radiotherapy of 4 Gy per fraction for limited-stage small cell lung cancer: a randomized pilot trial. PMID 40948832 · Transl Lung Cancer Res · 2025-Aug-31 The record is an oncology randomized pilot trial with human patients and time-to-event efficacy endpoints, but it is excluded because the intervention is radiotherapy-only (no drug-containing arm) and the phase/definitive nature is not established as Phase II/III or Phase III/IIIb.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Low-dose radiation and stereotactic body radiotherapy with PD-1 inhibitor sintilimab and chemotherapy for first-line treatment of locally advanced or metastatic squamous lung cancer: protocol for a randomised phase II trial (IHC002 study). PMID 40887121 · BMJ Open · 2025-Aug-31 方案论文未报告临床试验结果。
B
仅广召回影子组 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
Stereotactic body radiation therapy in oligometastatic pancreatic cancer: overall survival improvement and SMAD4 as a predictor of progression-free survival. PMID 40950337 · J Gastrointest Oncol · 2025-Aug-30 This is a retrospective cohort study, not a randomized controlled trial. It does not meet the core eligibility requirement of being a Phase III/IIIb or Phase II/III randomized trial.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Effects of 2-year cocoa extract supplementation on inflammaging biomarkers in older US adults: findings from the COcoa Supplement and Multivitamin Outcomes Study randomised clinical trial. PMID 40966617 · Age Ageing · 2025-Aug-29 The study is a randomized, placebo-controlled trial of a cocoa extract supplement, but it is not an oncology study. It focuses on inflammaging biomarkers in older adults, not on cancer outcomes. The primary endpoints are changes in biomarkers (hsCRP, IFN-γ, etc.), not time-to-event efficacy endpoints such as OS, PFS, or DFS. Therefore, it does not meet the eligibility criteria for inclusion in an oncology Kaplan-Meier digitization cohort.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Four-week remotely supervised aerobic exercise during the COVID-19 era: Exploring physical performance and psychosocial health in adults without COVID-19 living in rural settings. PMID 40898552 · Medicine (Baltimore) · 2025-Aug-29 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
B
仅广召回影子组 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Integrated Model of Cancer Control for Early Detection and Treatment in Adolescents and Young Adults Living With HIV: Protocol for a Cluster Randomized Controlled Trial. PMID 40882199 · JMIR Res Protoc · 2025-Aug-29 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
A comparative analysis of heterogeneity in lung cancer screening effectiveness in two randomised controlled trials. PMID 40877276 · Nat Commun · 2025-Aug-28 The record is a secondary analysis of heterogeneity in lung cancer screening effectiveness from two large RCTs. While it is a randomized human oncology study with results, it does not meet the core criteria: it is not a Phase III/IIIb or Phase II/III trial of a drug-containing intervention, and it does not report a primary/key secondary time-to-event efficacy endpoint (like OS, PFS, etc.) for such an intervention. The endpoint analyzed is screening effectiveness (mortality reduction), which is not a standard time-to-event endpoint for a drug trial.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
A phase 2 randomized study of modakafusp alfa as a single agent for patients with relapsed/refractory multiple myeloma. PMID 40279508 · Blood · 2025-Aug-28 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Longitudinal ctDNA Surveillance in Older Women with ER+ Breast Cancer to Facilitate Surgical De-Escalation: A Prospective, Hybrid-Decentralized Trial with Correlative Studies. PMID 40894139 · medRxiv · 2025-Aug-27 The record describes a non-randomized, correlative/prospective trial without a drug intervention, lacking clear Phase III/IIIb or Phase II/III evidence for a randomized drug evaluation.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Randomised trial of trastuzumab deruxtecan and biology-driven selection of neoadjuvant treatment for HER2-positive breast cancer: a study protocol of ARIADNE. PMID 40866060 · BMJ Open · 2025-Aug-27 方案论文未报告临床试验结果。
B
仅广召回影子组 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
Long-term oncological outcomes of indocyanine green fluorescence imaging-guided laparoscopic lymphadenectomy for gastric cancer: 5-year outcomes from the FUGES-012 randomized clinical trial. PMID 40859341 · BMC Med · 2025-Aug-26 干预为非药物单独策略,未满足药物干预要求。
B
仅广召回影子组 excludednon_drug_intervention pending 0 Figure · 0 Panel · risk -
Community navigation intervention for social needs in patients with abnormal mammography: a randomized controlled trial study protocol. PMID 40859259 · BMC Public Health · 2025-Aug-26 方案论文未报告临床试验结果。
B
仅广召回影子组 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
Opening of a phase Ib/II study to investigate the safety and efficacy of Afatinib in patients with Fanconi anemia and unresectable locally advanced or metastatic head and neck squamous cell carcinoma. PMID 40859225 · BMC Cancer · 2025-Aug-26 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -